Results 141 to 150 of about 9,230,509 (381)
Transmitter-replacement Therapy in Alzheimer's Disease Using Intracerebroventricular Infusions of Receptor Agonists [PDF]
, 1986 Serge Gauthier +12 more
openalex +1 more source
Advanced Healthcare Materials, EarlyView.This review explores how advanced materials enhance Bio‐FETs for precision healthcare and biosensing. It covers their working principles, surface functionalization, and ultra‐sensitive detection capabilities. The integration of flexible designs, AI, and IoT for real‐time monitoring is discussed, along with challenges like material reproducibility and ...
Minal Pandey +5 more
wiley +1 more source
Neurobiology of Disease, 2013 Deposition of amyloid β (Aβ) containing plaques in the brain is one of the neuropathological hallmarks of Alzheimer's disease (AD). It has been suggested that modulation of neuronal activity may alter Aβ production in the brain.
Xuejing Li +9 more
doaj
The Differential Diagnosis of Alzheimer's Disease: Conceptual and Methodological Issues [PDF]
, 1986 Mary C. Tierney +6 more
openalex +1 more source
Advanced Materials, EarlyView.This article summarizes significant technological advancements in materials, photonic devices, and bio‐interfaced systems, which demonstrate successful applications for impacting human healthcare via improved therapies, advanced diagnostics, and on‐skin health monitoring.
Seunghyeb Ban +5 more
wiley +1 more source
Challenges and Opportunities of Clinicopathological Investigation in Longitudinal Studies of Alzheimer's Disease [PDF]
, 1986 Melvyn J. Ball
openalex +1 more source
Smart Dust for Chemical Mapping
Advanced Materials, EarlyView.This review article explores the advancement of smart dust networks for high‐resolution spatial and temporal chemical mapping. Comprising miniature, wireless sensors, and communication devices, smart dust autonomously collects, processes, and transmits data via swarm‐based communication.
Indrajit Mondal, Hossam Haick
wiley +1 more source
Machine Learning Classification of Alzheimer's Disease Stages Using Cerebrospinal Fluid Biomarkers Alone [PDF]
arXivEarly diagnosis of Alzheimer's disease is a challenge because the existing methodologies do not identify the patients in their preclinical stage, which can last up to a decade prior to the onset of clinical symptoms. Several research studies demonstrate the potential of cerebrospinal fluid biomarkers, amyloid beta 1-42, T-tau, and P-tau, in early ...
arxiv